Recombinant Mouse Translocase of inner mitochondrial membrane domain-containing protein 1 (Timmdc1)

What is TIMMDC1 and what is its primary function in mitochondria?

TIMMDC1 (Translocase of Inner Mitochondrial Membrane Domain-Containing protein 1) functions as a critical subunit of complex I of the electron transport chain responsible for ATP production. Located in the mitochondrial inner membrane, it plays an essential role in energy metabolism by facilitating the assembly and stability of complex I .

In mouse models, TIMMDC1 demonstrates high conservation with the human ortholog and serves as an integral component of the IP (NDUFS2/NDUFS3/NDUFS7/NDUFS8) subcomplex during complex I biogenesis. The protein contains transmembrane domains that anchor it to the inner mitochondrial membrane, where it participates in the coordinated assembly of both membrane and matrix arms of complex I .

What experimental models are most suitable for studying mouse TIMMDC1 function?

Several experimental models are appropriate for investigating mouse TIMMDC1 function:

• Mouse embryonic fibroblasts (MEFs): Particularly useful for studying the basic cellular functions of TIMMDC1 in a native environment with preserved signaling pathways.

• CRISPR/Cas9-generated knockout/knockin mouse models: Allow for whole-organism evaluation of TIMMDC1 function and the physiological consequences of its deficiency.

• Patient-derived fibroblasts (for comparative studies): Though not mouse-specific, these can be valuable when comparing human and mouse TIMMDC1 function in parallel experiments .

• Neuronal cell cultures: Since TIMMDC1 deficiency has been associated with neurological disorders, primary neuronal cultures from transgenic mice can provide insights into tissue-specific effects .

When selecting a model, researchers should consider that complete TIMMDC1 knockout may be embryonically lethal due to its critical role in energy metabolism, making conditional or inducible systems preferable for long-term studies.

How can recombinant mouse TIMMDC1 be effectively expressed and purified?

Expression System Selection:
The optimal expression system for recombinant mouse TIMMDC1 requires careful consideration due to its transmembrane domains and mitochondrial localization.

Recommended Protocol:

• Vector Construction:

  • Clone the mouse Timmdc1 gene (without mitochondrial targeting sequence for cytosolic expression) into a vector with appropriate tags (His6, FLAG, or GST)

  • Include TEV protease cleavage sites if tag removal is desired

• Expression Systems Comparison:

• Purification Strategy:

  • Membrane solubilization using mild detergents (DDM or LMNG)

  • IMAC for His-tagged constructs

  • Size exclusion chromatography for final purity

• Quality Control:

  • Western blot analysis

  • Mass spectrometry

  • Functional assays (ATP production measurement)

The choice of expression system should be guided by the intended application of the recombinant protein, with mammalian systems preferred for structural studies and E. coli sufficient for antibody production.

What antibodies are recommended for mouse TIMMDC1 detection in various experimental applications?

When selecting antibodies for mouse TIMMDC1 detection, researchers should consider the specific application and required sensitivity:

Western Blotting:

• Polyclonal antibodies raised against multiple epitopes offer better detection sensitivity

• Look for antibodies validated specifically in mouse tissue lysates

• Expected molecular weight: approximately 31 kDa

Immunohistochemistry/Immunofluorescence:

• Monoclonal antibodies typically provide higher specificity for localization studies

• Confirm antibodies are validated for fixed tissue applications

Immunoprecipitation:

• Antibodies with high affinity for native conformation are essential

• Magnetic bead-conjugated antibodies often yield better results than agarose-based systems

Always validate antibodies in your specific experimental system, as cross-reactivity with other mitochondrial proteins can occur. Include appropriate positive controls (mouse heart or liver tissue, which express high levels of TIMMDC1) and negative controls (TIMMDC1 knockout samples if available).

How do TIMMDC1 mutations affect mitochondrial function and what models best recapitulate these defects?

TIMMDC1 mutations significantly impact mitochondrial function through disruption of complex I assembly and activity. In human patients, pathogenic variants in TIMMDC1 (such as the intronic c.597-1340A>G variant) lead to severe neurodegenerative phenotypes characterized by failure to thrive, hypotonia, peripheral neuropathy, and drug-resistant epilepsy .

Cellular Consequences of TIMMDC1 Deficiency:

• Complex I Assembly Defects:

  • Reduced abundance of complex I subunits

  • Accumulation of assembly intermediates

  • Compromised stability of the NADH dehydrogenase module

• Bioenergetic Dysfunction:

  • Decreased oxygen consumption rate

  • Reduced ATP production

  • Elevated ROS production

• Compensatory Responses:

  • Upregulation of other respiratory complexes

  • Metabolic shifting toward glycolysis

  • Mitochondrial network remodeling

Optimal Mouse Models:

For studying therapeutic approaches, mouse models carrying equivalent human pathogenic variants (such as the c.597-1340A>G intronic variant) provide the most relevant system for testing interventions like splice-switching antisense oligonucleotides (SSOs) .

What experimental approaches are most effective for studying TIMMDC1 interactions with other complex I assembly factors?

Understanding TIMMDC1's interactions with other complex I assembly factors requires a multi-faceted experimental approach:

Proximity-Based Protein Interaction Mapping:

• BioID or APEX2 Proximity Labeling:

  • Fusion of TIMMDC1 with a biotin ligase (BirA*) or APEX2

  • Enables identification of transient and stable interactors in the native mitochondrial environment

  • Superior to traditional pull-downs for membrane protein complexes

• Crosslinking Mass Spectrometry (XL-MS):

  • Captures direct protein-protein interactions through covalent crosslinking

  • Provides spatial constraints for structural modeling

  • Can identify interaction interfaces

• Co-Immunoprecipitation with Sequential Protein Extraction:

  • Differential detergent extraction to distinguish membrane-dependent interactions

  • Coupled with quantitative proteomics for interaction strength estimation

Interaction Validation and Characterization:

Based on Reactome pathway data, TIMMDC1 interacts with multiple assembly factors during complex I biogenesis, particularly during the formation of Intermediate 1 where it associates with NDUFAF3 and NDUFAF4 .

For comprehensive interaction mapping, combine these approaches with super-resolution microscopy to visualize the spatiotemporal dynamics of complex I assembly intermediates containing TIMMDC1.

How can antisense oligonucleotides be designed to modulate mouse TIMMDC1 expression for therapeutic applications?

Antisense oligonucleotides (SSOs) represent a promising therapeutic approach for TIMMDC1-related disorders, as demonstrated in human patient-derived cells . For mouse models, the design principles remain similar but require mouse-specific sequence considerations:

SSO Design Principles for Mouse TIMMDC1:

• Target Selection:

  • Identify mouse-specific splice regulatory elements

  • Focus on evolutionary conserved intronic regions when targeting equivalent human mutations

  • Prioritize regions with accessible secondary structure

• Chemistry Optimization:

• Delivery Systems for CNS Targeting:

  • Direct intracerebroventricular injection

  • BBB-penetrating peptide conjugation

  • Nanoparticle encapsulation

In a study with human patient cells carrying the c.597-1340A>G TIMMDC1 variant, two different SSOs were designed to restore normal TIMMDC1 mRNA processing and protein levels. Similar approaches in mouse models would require:

• Careful mapping of the mouse Timmdc1 intronic regions

• Identification of mouse-specific splicing regulatory elements

• Screening multiple SSO candidates in mouse cell culture before in vivo application

• Quantitative assessment of complex I restoration using proteomic and functional assays

This therapeutic approach has particular relevance for genetic variants affecting splicing, which represent a significant portion of pathogenic TIMMDC1 mutations.

What proteomics approaches best assess the impact of TIMMDC1 deficiency on mitochondrial complex I assembly?

Comprehensive assessment of TIMMDC1 deficiency effects on complex I assembly requires sophisticated proteomics methodologies that can capture both compositional and structural changes:

Quantitative Mitochondrial Proteomics Workflow:

• Sample Preparation Options:

  • Highly purified mitochondria from control and TIMMDC1-deficient samples

  • Blue Native PAGE fractionation to separate intact complexes

  • Sucrose gradient ultracentrifugation for assembly intermediate isolation

• Quantification Strategies:

• Complex I Assembly-Specific Approaches:

  • Complexome profiling (combines BN-PAGE with mass spectrometry)

  • Pulse-SILAC to monitor assembly kinetics

  • Crosslinking mass spectrometry for structural changes

Data from human patient fibroblasts with TIMMDC1 deficiency showed that quantitative proteomics coupled with real-time metabolic analysis can effectively demonstrate restoration of complex I subunit abundance and function following therapeutic intervention . Similar approaches in mouse models can provide mechanistic insights into assembly defects and identify potential compensatory mechanisms.

The most informative approach combines multiple techniques, including complexome profiling to identify stalled assembly intermediates alongside functional respiratory chain measurements to correlate proteome changes with bioenergetic consequences.

What are the challenges in developing therapeutic strategies for TIMMDC1-related disorders based on mouse model findings?

Developing effective therapeutics for TIMMDC1-related disorders presents several significant challenges that must be addressed when translating findings from mouse models to human applications:

Translational Challenges from Mouse to Human:

• Genetic and Phenotypic Differences:

  • Mouse Timmdc1 has subtle sequence divergence from human TIMMDC1

  • Phenotypic severity may differ between species

  • Cell-type specific vulnerabilities may not be fully conserved

• Mitochondrial Complex I Composition Differences:

• Therapeutic Delivery Challenges:

  • Blood-brain barrier penetration limitations

  • Achieving therapeutic concentrations in affected tissues

  • Potential immune responses to recombinant proteins

  • Differences in drug metabolism between species

A promising therapeutic approach demonstrated in human patient fibroblasts involves splice-switching antisense oligonucleotides (SSOs) designed to restore normal TIMMDC1 mRNA processing and protein levels. This approach successfully restored complex I subunit abundance and function in cellular models .

For successful translation of this approach:

• Mouse-specific SSO sequences would need to be adapted for human application

• Delivery methods optimized in mice would require adjustment for human physiology

• Dosing regimens established in mice would need clinical recalibration

• Long-term safety profiles would require extensive assessment beyond typical mouse lifespan

The rare nature of TIMMDC1-related disorders (with variants like c.597-1340A>G present at approximately 1/5000 frequency in human populations) also complicates clinical trial design and necessitates careful patient selection strategies to demonstrate therapeutic efficacy.

What are the most promising research directions for TIMMDC1 studies?

The investigation of TIMMDC1 represents an important frontier in mitochondrial medicine, with several promising research directions:

• Structure-Function Relationships: Determining the precise structural role of TIMMDC1 in complex I assembly using cryo-EM and advanced structural biology approaches.

• Tissue-Specific Functions: Exploring the differential requirements for TIMMDC1 across tissues, particularly in high-energy demanding cells like neurons and cardiomyocytes.

• Therapeutic Development: Expanding antisense oligonucleotide approaches to target various TIMMDC1 mutations, potentially offering personalized medicine solutions for patients with mitochondrial disorders .

• Compensatory Mechanisms: Identifying cellular pathways that can compensate for TIMMDC1 deficiency, potentially revealing new therapeutic targets.

• Biomarker Discovery: Developing reliable biomarkers for TIMMDC1 dysfunction that could be used for diagnosis and monitoring treatment efficacy.